> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Review Voucher Awarded on Viltepso OK
- URL: https://www.fdaweb.com/priority-review-voucher-awarded-on-viltepso-ok/
- Published: 2020-09-04T12:00:00.000Z
- Updated: 2026-09-14T16:27:46.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147591

*Federal Register* notice: FDA has issued Nippon Shinyaku a priority review voucher after approval of its rare disease drug Viltepso (viltolarsen), indicated for treating Duchenne Muscular Dystrophy in patients amenable to Exon 53 skipping. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-09-04/pdf/2020-19604.pdf?ref=fdaweb.com).